Business
American Diversified Holdings Corporation (ADHC) Completes Acquisition Of GlucoGuard, a AI-Based Medical Device for Managing Nocturnal Hypoglycemia in Diabetic Patients
American Diversified Holdings Corporation (ADHC) Completes Acquisition Of GlucoGuard, a AI-Based Medical Device for Managing Nocturnal Hypoglycemia in Diabetic Patients.
About this update from American Diversified Holdings Corp.
[{"type":"text","content":"Del Mar, California--(Newsfile Corp. - September 30, 2024) - American Diversified Holdings Corporation (OTC Pink: ADHC) is pleased to announce the completion of the previously announced acquisition of GlucoGuard, a revolutionary AI-driven medical device technology from IMD Solutions, Phoenix, AZ. GlucoGuard is designed to address the critical challenge of managing nocturnal Hypoglycemia for diabetic patients, offering a breakthrough in non-invasive, continuous glucose monitoring and delivery.Other recent developments are underway that are extremely beneficial in ADHC capitalization structure paving the way for enhancing shareholder value.Elimination of $2.7 mm in Corporate Debt creating a \"DEBT FREE\" company.144 Million Share Cancellation is underway via the legal process.Fiscal Year End Financials have been filed with OTC markets. (Period Ending 7-31-24).Global Distribution of ADHC's Corporate Information is Underway, including Europe, Asia, North and South America.Share Holders can expect many exciting and transformative updates to be released soon.COMPANY OVERVIEWIn addition to the completed acquisition, GlucoGuard's founder, Zachary Smith, BS/MS Biomedical Engineering (Arizona State University), will join ADHC's advisory board. Smith will work alongside Bill Colone, a renowned expert in biomedical solutions, to advance GlucoGuard's development and integration into ADHC's expanding healthcare technology portfolio.The terms of the acquisition remain undisclosed, but financing is expected to be non-dilutive.Transforming Diabetes ManagementZachary Smith commented, \"ADHC provides the ideal platform for the commercialization of GlucoGuard. Both Bill and I are eager to bring this life-saving technology to market, helping millions of diabetic patients-both adults and children-better manage their glucose levels with greater safety and ease.\"Bill Colone added, \"Hypoglycemia, particularly during sleep, is a persistent and dangerous issue for diabetic patients, often leading to serious consequences like the dreaded 'Death in Bed' syndrome. GlucoGuard's technology offers a game-changing solution to this pressing problem.\"Key Development PartnershipsThe GlucoGuard system is being developed in collaboration with three key partners:A leading U.S. research university.A highly respected biomedical and defense engineering firm.A top publ...